Results 31 to 40 of about 56,757 (311)

MS Spasticity: Take Control (STC) for ambulatory adults: protocol for a randomized controlled trial

BMC Neurology, 2020
Background Spasticity affects 60–80% of people with multiple sclerosis (MS), impacting activity, participation and quality of life. We developed the group delivered spasticity self-management program, “MS Spasticity: Take Control” (STC), with DVDs for ...
Cinda L. Hugos, Michelle H. Cameron
doaj   +1 more source

sj-pdf-2-jhs-10.1177_17531934231192843 - Supplemental material for Expert consensus on the surgical evaluation and management of upper extremity spasticity in adults

, 2023
Supplemental material, sj-pdf-2-jhs-10.1177_17531934231192843 for Expert consensus on the surgical evaluation and management of upper extremity spasticity in adults by Christopher S. Crowe, Paula A. Pino and Peter C.
Christopher S. Crowe (1887055), Peter C. Rhee and the Upper Extremity Spasticity Working Group (16998357), Paula A. Pino (16998354)   +2 more
core   +1 more source

sj-pdf-3-jhs-10.1177_17531934231192843 - Supplemental material for Expert consensus on the surgical evaluation and management of upper extremity spasticity in adults

, 2023
Supplemental material, sj-pdf-3-jhs-10.1177_17531934231192843 for Expert consensus on the surgical evaluation and management of upper extremity spasticity in adults by Christopher S. Crowe, Paula A. Pino and Peter C.
Christopher S. Crowe (1887055), Peter C. Rhee and the Upper Extremity Spasticity Working Group (16998357), Paula A. Pino (16998354)   +2 more
core   +1 more source

Canadian Physicians’ Use of Ultrasound in Spasticity Treatment: A National Cross-Sectional Survey

Archives of Rehabilitation Research and Clinical Translation
Objective: To identify potential barriers and obstacles preventing clinicians from adopting ultrasound for spasticity management. Design: A prospective, cross-sectional national survey. Setting: Web-based platform. Participants: Thirty-six physicians and
Fraser MacRae, BSc, Ève Boissonnault, MD, Alto Lo, MD, Heather Finlayson, MD, Paul Winston, MD, Omar Khan, MD, Heather Dow, Farris Kassam, BSc, Rajiv Reebye, MD   +8 more
doaj   +1 more source

Integrated Management of Multiple Sclerosis Spasticity and Associated Symptoms Using the Spasticity-Plus Syndrome Concept: Results of a Structured Specialists' Discussion Using the Workmat® Methodology

Frontiers in Neurology, 2021
Background: Multiple sclerosis (MS) treatment has radically improved over the last years; however, MS symptom management is still challenging. The novel Spasticity-Plus syndrome was conceptualized to frame several spasticity-related symptoms that can be ...
Oscar Fernandez, Lucienne Costa-Frossard, Maria Luisa Martínez-Ginés, Paloma Montero, Jose María Prieto-González, Lluís Ramió-Torrentà, Lluís Ramió-Torrentà, Lluís Ramió-Torrentà   +7 more
doaj   +1 more source

Assessing muscle architecture with ultrasound: implications for spasticity

European Journal of Translational Myology
Botulinum Neurotoxin Type A (BoNT-A) injections using Ultrasound (US) guidance have led to research evaluating changes in muscle architecture. Controversy remains as to what constitutes increased Echo-Intensity (EI) in spastic muscles and whether this ...
Ève Boissonnault, April Hyon, Michael C. Munin, Mirko Filippetti, Alessandro Picelli, Chloe Haldane, Rajiv Reebye   +6 more
doaj   +1 more source

Non‐interventional, prospective, observational study on spasticity‐associated symptom control with nabiximols as add‐on therapy in patients with multiple sclerosis spasticity in Austria

Brain and Behavior, 2023
Background and purpose Randomized controlled trials and observational studies of nabiximols oromucosal spray in patients with multiple sclerosis (MS) spasticity have shown improvement in a range of associated symptoms (pain, spasms, fatigue, bladder ...
Michael Guger, Robert Hatschenberger, Fritz Leutmezer   +2 more
doaj   +1 more source

Developmental and Epileptic Encephalopathy due to Biallelic Pathogenic Variants in PIGM

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective PIGM encodes a critical enzyme in the glycosylphosphatidylinositol (GPI)‐anchor biosynthesis pathway. While promoter‐region mutations in PIGM have been associated with a relatively mild phenotype characterized by portal vein thrombosis and absence seizures, recent evidence suggests that coding‐region mutations result in a more severe
Júlia Sala‐Coromina, Anna Marcé‐Grau, Barbara Masotto, Marta Codina, Lamia BenJemaa, Yasmina Elaribi, Mónica Martinez‐Gallo, Roger Colobran, Angel Sanchez‐Montañez, Irene Valenzuela, Yoshiko Murakami, Alfons Macaya   +11 more
wiley   +1 more source

SPASTIC CYCLOPHORIA. [PDF]

The Lancet, 1913
n ...
openaire   +2 more sources

Clinical Validation of Plasma p‐217tau in Neurological Diseases

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Plasma p‐217tau is a minimally invasive but specific biomarker for diagnosing Alzheimer's disease (AD). However, its disease specificity remains to be clinically evaluated. We validated the reliability of the p‐217tau biomarker in 12 other neurological diseases.
Takeshi Kawarabayashi, Takumi Nakamura, Ryoma Takahashi, Tetsuya Ueda, Seiji Kinoshita, Chikage Uchida, Takashi Sugawara, Kentaro Hashimoto, Kunihiko Ishizawa, Masakuni Amari, Hiroo Kasahara, Yoshio Ikeda, Masamitsu Takatama, Mikio Shoji   +13 more
wiley   +1 more source